Belvarafenib 50mg QD Cobi 20mg QOD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	MEL-JUSO Belvarafenib 200mg BID Cobi 40mg QD		MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD	MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD		MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	MEL-JUSO Belvarafenib 200mg BID Cobi 60mg QD	MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
GRvalue Winderfinite Winderfini	GRvalue 1.0 0.5 0.0 WEXT OF THE REPORT O	GRvalue Wn -2 - 0.5 0.5 0.0 WE KING OO -0.5 -3 -3 -	GRvalue	GRvalue 1.0 Mn qui jum qoo jum		GRvalue 1.0 Who quite display to the second of the second	GRvalue win quiun administration of the state of the stat		GRvalue 1.0 Who -2 - 0.5 Light of the light	GRvalue	GRvalue 1.0 Wn qiujamuqinipam		GRvalue 1.0 Who quipequipequipequipequipequipequipequipe	GRvalue - 1.0 Wn -2 - - 0.5 Wn Qiuinetining - 0.5 -3 -	GRvalue 1.0 0.5 0.0 -0.5	-1- WEKI CODIMENTING MARKING TO A STATE OF THE PARTY OF T	GRvalue 1.0 Win -2 - 0.5 0.0 UKK N -3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 -
4	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	_4		panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess Win quiting may 2 - 0.5 0.0 0.0 0.0 -0.5 Win quiting may 2 - 0.5 -0.5 -0.5 -1.0 -3 - 3	HSA Excess -1.0 -0.5 -0.5 -0.5 -1.0 -3 -	HSA Excess 1.0 0.0 -0.5 -1.0 -3	HSA Excess I.0 O.5 O.5 O.5 I.0 O.6 I.0 O.7 III III III III III III III	HSA Excess 1.0 0.0 -0.5 -0.5 -1.0 -1.0 -3	HS 3 B 3 B 3 B 3 B 3 B 3 B 3 B 3 B 3 B 3	HSA Excess 1.0 0.5 0.0 0.0 -0.5 -1.0 -3	HSA Excess When the state of t		SA Excess 1.0 0.0 -0.5 WE WILLIAM TO THE TENT OF THE T	HSA Excess 1.0 0.5 0.0 -0.5 -0.5 -1.0 -3	HSA Excess 1.0 0.0 -0.5 WEY -1.0 -3 -		HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3 -	HSA Excess 1.0 O.0 O.0 O.0 O.5 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0	WEKi Copimetinib uM	HSA Excess 1.0 0.0 -0.5 -0.5 -1.0 -3
	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 40mg QD	-4 -3 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg BID Cobi 40mg QD		-3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 50mg QD Cobi 60mg QD	4	-3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 100mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 200mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM MEL-JUSO Belvarafenib 400mg BID Cobi 60mg QD
Bliss Excess 1.0 0.5 0.0 0.0 0.7 3 -1.0 -3	Bliss Excess 1.0 0.0 0.0 Vin quipaurigo O I Jyaw -0.5 -0.5 -1.0 -3	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.0 0.0 1.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3	Bis	Bliss Excess 1.0 0.5 0.0 0.0 1.0 0.5 0.0 0.0 -0.5 -1.0	-1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -		-1- iss Excess 1.0 White is a series of the	Bliss Excess 1.0 0.5 0.0 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.0 -0.5 -1.0 -3		Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 Wn -2 - 0.5 in the property of the property o	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0	The state of the s	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3
-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD	-4 -3 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID Cobi 40mg QD	-2 -4	-3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD	-4	-3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID Cobi 60mg QD
GRyalue Win quinaeurigo Jos Jos Jos Jos Jos Jos Jos J	GRvalue WEXI-Copiumetrials O.5 O.5 -O.5 -O.5 -3-	GRvalue 1.0 Wn quinipun quinip	GRvalue 1.0 Wn quipamiquo 0.5 0.5 -0.5 -3-	GRvalue		GRvalue 1.0	GRyalue The state of the state		GRvalue 1.0	GRvalue 1.0 Wn -2 - 0.5 Waging and the state of the stat	GRvalue 1.0		GRvalue 1.0 Wn qui in	GRvalue 1.0	GRvalue 1.0 0.5 0.0 -0.5	MEKi_Copimetinib uM -2 -3 -3	GRvalue 1.0 Wh quipaeling on the state of t
SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QOD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 200mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QOD	SK-MEL-2 Belvarafenib 50mg QD Cobi 20mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 200mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 20mg QD	SK-MEL-2 Belvarafenib 50mg QD Cobi 40mg QD	SK-MEL-2 Belvarafenib 100mg BID Cobi 40mg QD	SK-MEL-2 Belvarafenib 200mg BID Cobi 40mg QD		SK-MEL-2 Belvarafenib 400mg BID Cobi 40mg QD	SK-MEL-2 Belvarafenib 50mg QD Cobi 60mg QD		SK-MEL-2 Belvarafenib 100mg BID Cobi 60mg QD	SK-MEL-2 Belvarafenib 200mg BID Cobi 60mg QD	SK-MEL-2 Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess Win quijaugoo Oo O	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.0 0.0 1.0 1.0 3	HS B B B B B B B B B B B B B B B B B B B	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 WEKION THE PROPERTY OF THE		SA Excess 1.0 0.0 0.0 1.0 -0.5 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.0 -0.5 0.0 -0.5 -1.0 -3 -		HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.0 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0	WEKi_Cobimetrinib uM -2 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3
panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID	-	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 50mg QD	•	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 100mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 200mg BID	panRAFi_Belvarafenib uM SK-MEL-2 Belvarafenib 400mg BID
Cobi 20mg QOD -1 -1 -1 -1 -1 -1 -1 -1 -1 -	Bliss Excess 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	Bliss Excess 1.0 0.0 -0.5 -0.5 -1.0 -1.0 -3	Bliss Excess 1.0 0.5 0.0 1.0 -1.0 -3	Bliss Excess 1.0 0.0 -0.5 -1.0 -3	Blis	Bliss Excess 1.0 0.5 0.0 0.0 0.0 -0.5 -1.0 -3 -4 -4 -3 -3 -2	Bliss Excess 1.0 0.5 0.0 0.0 -0.5 -1.0 -1.0	Bi -4 -3 -2	iss Excess 1.0 0.0 0.0 0.7 1.0 -0.5 -1.0 -3 -4 -4 -3 -2	Bliss Excess 1.0 White distribution of the properties of the pro	Bliss Excess 1.0 0.0 -0.5 -1.0 -3 -4		Bliss Excess 1.0 0.0 -0.5 -1.0 -3 -4 -4 -3 -2	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3 -4	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0	WEK! Copineting of the state of	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3 -3 -3 -2
Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QOD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 20mg QD	Cobi 40mg QD	Cobi 40mg QD	Cobi 40mg QD	1	Cobi 40mg QD	Cobi 60mg QD	I	Cobi 60mg QD	Cobi 60mg QD	Cobi 60mg QD
GRvalue Wn Quinterline (Grown) GRvalue A A A A A A A A A A Belivarafenib uM SK-MEI - 30	GRvalue 1.0 Wa -2 0.5 0.0 Na parity and the second of	GRvalue Joseph	GRvalue 1.0 0.5 0.0 0.0 1.0 1.0 1.0 1.0	GRvalue yn quijau igoo jos jos jos jos jos jos jos jos jos j	-4 -3 -2 panRAFi_Belvarafenib uM	GRvalue 1.0	GRvalue In the second of the	panRAFi_Belvarafenib uM	GRvalue 1.0 Visual Line 1.0	GRvalue 1.0 Who distributed the second of t	GRvalue 1.0 Win qiuitamiqoo 0.5 0.0 -0.5 -3 -4	panRAFi_Belvarafenib uM	GRvalue 1.0 0.5 0.0 0.0 -0.5 -0.5 -3 panRAFi_Belvarafenib uM	GRvalue 1.0 0.5 0.0 Na William 1.0 0.0 -0.5 -3 -4	GRvalue 1.0 0.5 0.0 -0.5 panRAFi_Belvarafenib uM	MKEKI Coping (Mark) And Andrews (Mark) Andrews (Mar	GRvalue 1.0 0.5 0.0 -0.5 -3 panRAFi_Belvarafenib uM
Belvarafenib 50mg QD Cobi 20mg QOD	Belvarafenib 100mg BID Cobi 20mg QOD	Belvarafenib 200mg BID Cobi 20mg QOD	Belvarafenib 400mg BID Cobi 20mg QOD	Belvarafenib 50mg QD Cobi 20mg QD	Belvarafenib 100mg BID Cobi 20mg QD	Belvarafenib 200mg BID Cobi 20mg QD	Belvarafenib 400mg BID Cobi 20mg QD	Belvarafenib 50mg QD Cobi 40mg QD	Belvarafenib 100mg BID Cobi 40mg QD	Belvarafenib 200mg BID Cobi 40mg QD		Belvarafenib 400mg BID Cobi 40mg QD	Belvarafenib 50mg QD Cobi 60mg QD		Belvarafenib 100mg BID Cobi 60mg QD	Belvarafenib 200mg BID Cobi 60mg QD	Belvarafenib 400mg BID Cobi 60mg QD
HSA Excess 1.0 0.0 0.0 0.0 -0.5 Where the second of the se	HSA Excess 1.0 0.0 0.0 -0.5 -1.0 -3 -	HSA Excess 1.0 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.0 -0.5 -1.0 -3 -	HSA Excess 1.0 0.0 0.0 -0.5 -1.0 -3	HS B B B B B B B B B B B B B B B B B B B	HSA Excess 1.0 0.5 0.0 0.0 1.0 0.5 0.0 -0.5 -1.0 -3-	HSA Excess 1.0 0.5 0.5 0.0 0.0 1.0 We William of the control of th		SA Excess 1.0 0.0 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -0.5 -1.0 -3	HSA Excess 1.0 0.5 0.0 -0.5 -1.0 -3 -		HSA Excess 1.0 0.0 0.0 -0.5 -1.0 -3	HSA Excess 1.0 0.0 0.0 -0.5 -1.0 -3 -	HSA Excess 1.0 0.5 0.0 -0.5 -1.0	MEKI_Cobimetinib uM	HSA Excess 1.0 0.0 -0.5 -1.0 -3
-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg BID Cobi 20mg QOD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QOD	-4 -3 -3 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg BID Cobi 20mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 20mg QD	panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 40mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 40mg QD			panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 40mg QD	-43 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 50mg QD Cobi 60mg QD		panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 100mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 200mg BID Cobi 60mg QD	-4 -3 -2 panRAFi_Belvarafenib uM SK-MEL-30 Belvarafenib 400mg BID Cobi 60mg QD
Bliss Excess -0.5 -0.5 -1.0 -3 panRAFi_Belvarafenib uM	Bliss Excess 1.0 0.0 0.0 0.0 -0.5 -1.0 -3 -3	Bliss Excess -1- 0.5 0.0 0.0 -0.5 -1.0 -3 -4	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3 -4	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3	Blis 3 3 3 4 -3 -2	Bliss Excess 1.0 0.5 0.0 0.0 0.0 -0.5 -1.0 -3 -4 -3 -3 -2	Bliss Excess 1.0 0.5 0.5 0.0 0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Bi	iss Excess 1.0 0.0 0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.0 -0.5 -1.0 -3 -4	-3 -2	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.0 0.0 -0.5 -1.0 -3	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0	-1 - B - 3 - 3 - 2	Bliss Excess 1.0 0.5 0.0 -0.5 -1.0 -3 Bliss 1.0 -3 -3 -3 -3